Prevalence of Chronic Backpain after COVID-19 Astrazeneca and Pfizer/Biontech Vaccines in Sultanate of Oman: A Survey-Based Study

Nasir A. Hamad^1*, Lienda Bashier Eltayeb², Priyanka Raj³ and Senthilvel Vasudevan⁴

¹Department of Biochemistry, College of Medicine and Health Sciences , Al-Neelain University, Sudan. National University, Oman.

²Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University- Al-Kharj, Riyadh, KSA.

³Department of Epidemiology, Public Health and Biostatistics, College of Medicine and Health Sciences, National University, Oman.

⁴Department of Community Medicine, Sri Venkateshwara Medical College, India.

Corresponding Author E-mail: nasirrafie@nu.edu.om

Abstract: Introduction: Covid-19 vaccine is known to cause a variety of side effects. Low back pain has been reported to be associated with at least one of the COVID-19 vaccines. Objectives: The current study investigated the prevalence of chronic back pain in individuals vaccinated with AstraZeneca and Pfizer in Sultanate of Oman. Methods: This cross-sectional observational survey-based study was conducted among COVID-19 AstraZeneca and Pfizer/BioNTech vaccinated individuals in Sultanate of Oman. Two hundred participants were involved in the study. Chi square was used to analyse the association between categorical data. Data were analysed using SPSS (29^th release). Results: The prevalence of back pain among individuals vaccinated with AstraZeneca and Pfizer, was 36%. Females were more commonly affected by the back pain, especially in the 4^th decade of life. Conclusion: AstraZeneca and Pfizer is be associated with back pain, especially in females. Possible explanations require further investigations.

Keywords: Astrazeneca; Chronic Backpain; COVID-19; Frequency; Pfizer; Vaccine

[ HTML Full Text]

Back to TOC